Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03924245
Recruitment Status : Recruiting
First Posted : April 23, 2019
Last Update Posted : July 15, 2021
Sponsor:
Collaborators:
AstraZeneca
Syndax Pharmaceuticals
Information provided by (Responsible Party):
Marta Crispens, MD, Vanderbilt-Ingram Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : September 2026